LB Pharmaceuticals has started its pivotal Phase III NOVA-2 trial to assess the safety and efficacy of its investigational ...

AstraZeneca’s IL-33 blocker, tozorakimab has significantly reduced the annualised rate of COPD exacerbations as an adjuvant to SoC inhaled therapy over placebo in two Phase III studies. Credit: ...

Thermo Fisher Scientific has completed the acquisition of Clario, a clinical trial endpoint data solutions supplier, in an $8 ...

J&J was keen to highlight that these trial results do not invalidate tau as a therapeutic target for Alzheimer’s disease; the ...

Insmed will now seek Arikayce’s approval in the US and Japan for use in earlier lines of MAC lung infection treatment.

Maze is catching up with Vertex which is also developing a drug with the same target for APOL1-mediated kidney disease.

A novel oral vaccine, ETVAX, has demonstrated its potential to reduce paediatric cases of moderate-to-severe enterotoxigenic ...

Roche will no longer progress emugrobart to late-stage trials in FSHD and SMA, as the drug has failed to demonstrate ...

Despite failing to achieve one of the co-primary endpoints of the SENTRY study, Karyopharm will still approach the FDA for ...

Avalyn has initiated the AURA Phase II clinical trial assessing the efficacy and safety of AP02, inhaled nintedanib delivered ...

Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.

YolTech Therapeutics has received clearance from the US FDA to begin a Phase II/III clinical study of its in vivo ...